Retia Medical Appoints Former Baxter Executive Christopher Benassi to Advisory Board

Retia Medical, a company specializing in cardiovascular intelligence software, announced the appointment of Christopher Benassi to its Strategic Advisory Board. Benassi is the former Vice President of the Connected Care Group at Baxter International, bringing over 15 years of leadership experience in the healthcare and medtech industries.

The appointment coincides with a period of significant growth for Retia Medical. The company received FDA 510(k) clearance for its Argos Infinity platform in February 2026 and has since initiated commercial deployments in virtual and tele-ICU environments. Retia Medical's annual revenue has grown sixfold over the past two years.

Benassi's expertise includes connected care, software-based monitoring, commercial strategy, mergers and acquisitions, and corporate venture capital. At Baxter, he led a high-growth business focused on communications, software, artificial intelligence, and critical care monitoring technologies.

"Having spent years at the forefront of connected care, I've seen firsthand what it takes to build a durable software and monitoring franchise," Benassi stated. "Retia has built something genuinely differentiated with clinical evidence, regulatory achievement, and commercial execution that is exceptional for a company of this size. I'm joining Retia's Strategic Advisory Board because I believe the most important chapter of this company is still ahead."

Retia Medical develops software that transforms physiological monitoring data into actionable clinical insights to improve patient outcomes in cardiovascular care. The company aims to enhance early detection and management of cardiovascular conditions through its FDA-cleared Argos Infinity platform, which operates on existing hospital infrastructure.